What the Business Does
Johnson & Johnson (JNJ) operates within the healthcare sector, specifically in the drug manufacturing industry. The company is known for its diverse product portfolio, which includes pharmaceuticals, medical devices, and consumer health products. JNJ's strong brand presence and innovation capabilities contribute to its competitive edge in a rapidly evolving healthcare landscape.
The Buffett-Framework Verdict
According to the Buffett framework, Johnson & Johnson scores a total of 64, earning a grade of B. The verdict is classified as unclear, indicating a mixed outlook for potential investors. Here’s a breakdown of the key pillar scores:
- Moat: 79 - JNJ boasts strong pricing power with a gross margin of 69.1% and an operating margin of 26.9%.
- Durability: 53 - Concerns arise from patent and litigation risks, reflected in a worst-case earnings decline projection of 58%.
- Management: 80 - The management's focus on shareholder returns is evident through consistent share buybacks and disciplined capital allocation.
- Valuation: 28 - At a price-to-earnings (P/E) ratio of 26.9, JNJ is seen as overvalued in the current market.
- Financial Health: 75 - JNJ maintains a fortress balance sheet, with a debt-to-equity ratio of just 0.22 and negative net debt to EBITDA, indicating robust financial stability.
Valuation and Margin of Safety
Currently, Johnson & Johnson's stock price stands at $228.39, with a market capitalization of approximately $549.78 billion. The P/E ratio of 26.93 suggests that investors are paying a premium for the stock. The company’s owner-earnings yield is only 3.53%, indicating a lack of margin of safety for new investors. Additionally, the enterprise value to earnings before interest and taxes (EV/EBIT) ratio of 21.6 further emphasizes the high valuation.
The Bull Case
Supporters of JNJ highlight several strengths:
- The company has a proven ability to generate consistent earnings growth, evidenced by an annual EPS growth rate of 8.6%, which outpaces its revenue growth of 4.6%.
- JNJ's management is committed to shareholder-friendly practices, including a share count reduction of about 2% annually through buybacks.
- The robust interest coverage ratio of 32 times indicates that debt servicing is manageable relative to earnings, enhancing financial security.
- With a five-year return on invested capital (ROIC) around 21%, JNJ demonstrates a capacity to reinvest profits effectively.
The Bear Case
Conversely, several concerns could impact JNJ's future performance:
- The steep valuation at 26.9 times earnings raises questions about future growth prospects.
- The durability score of 53 suggests potential vulnerabilities, particularly related to patent expirations and ongoing litigation, which could adversely affect earnings.
- A notable decline in the return on capital, dropping from 21% to 13.6% in the trailing year, raises alarms about operational efficiency.
- Limited revenue growth of 4.6% indicates that JNJ may be reaching maturity, necessitating constant innovation to maintain its market position.
- Free cash flow represents only 73% of net income, suggesting that reported earnings may not accurately reflect actual cash generation.
The Bottom Line
Johnson & Johnson is a well-established player in the healthcare sector with a strong balance sheet and significant pricing power. However, the current valuation appears steep, and the potential for future growth is uncertain. Investors should weigh these factors carefully when considering an investment in JNJ.
This is educational, not financial advice. For further insights, check the Buffett verdict and explore the stock page.